PAGE 18
HIV NUTRITION UPDATE
VOLUME 7, ISSUE 5
(Return to page 17)
 
By William Palumbo, MS, RD, CDN
Brand Name: Pravachol

Therapeutic Category: Antilipemic Agent, HMG-CoA Reductase Inhibitor

Use: Primary prevention of coronary events: In combination with medical nutrition therapy (MNT) in hypercholesterolemic patients without established coronary heart disease.

Secondary prevention of coronary events: In combination with MNT  with established coronary heart disease; to slow the progression of coronary atherosclerosis.

Hyperlipidemias: As an adjunct to MNT to reduce elevations in total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, and triglycerides.
 
 
Contraindications: Hypersensitivity to pravastatin or any component of the formulation, active liver disease, unexplained persistent elevations of serum transaminases; pregnancy; and breastfeeding.

Warnings/Precautions: To lessen the possibility of myopathy, patients should not take pravastatin with high dose niacin. Use with caution in patients who consume large amounts of ethanol or have a history of liver disease. May elevate aminotransferases; liver function tests (LFT’s) should be performed before therapy, prior to elevation of dose, and periodically thereafter. Can also cause myalgia and rhabdomyolysis. Risk is increased with concurrent use of clarithromycin, danazol, diazepam, fluvoxamine, indinavir, nefazodone, nelfinavir, ritonavir, verapamil, troleeaandomycin, cyclosporine, fibric acid derivatives, erythromycin, niacin, or azole antifungals.

Adverse Reactions: Abdominal cramps, chest pain, diarrhea, dyspepsia, fatigue, heartburn, myalgia, nausea, vomiting. 
 

 

"Use with caution in patients who consume large amounts of ethanol or have a history of liver disease."

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Interactions:

Cytochrome P450 Effect: CYP3A3/4 enzyme substrate

Increased Effect/Toxicity: Clofibrate, fenofibrate, gemfibrozil, and niacin may increase the risk of myopathy and rhabddommyolysis. Imidazole antifungals (itraconazole, ketoconazole, P-glycoprotein inhibitors )may increase pravastatin concentrations.

Decreased effect: Concurrent administration of cholestyramine or colestipol can decrease pravastatin absorption.

(Continued on page 19)


 

No part of this newsletter may be reproduced in any form without permission from the publisher. Copyright 2003 HIV ReSources, Inc. Email: subscriptions@hivresources.com


 
 
 

 
 
Copyright 2003 HIV ReSources, Inc. Sharing this newsletter in any form with non-subscribers is strictly prohibited. Library/Institution subscribers are permitted to share HIV Nutrition Update html newsletter pages with up to five (5) employees or volunteers. NO other redistribution allowed. 
 
Please Help To Keep This Page Updated By Notifying
The Webmaster If You Find A Link That's Outdated!
 
HIV ReSources, Inc.
PO Box 39385
Fort Lauderdale, FL
33339-9385
USA
 
© 2003  HIV ReSources, Inc.
Any use of the information presented herein is done strictly at your own risk.
No responsibility is implied or intended on the part of HIV ReSources Inc,
the editor, or the publisher. Information on this site should not
be construed as an endorsement of any kind.
 
3/30/2003